Author: Editor

Rafael G Amado, MD, Adaptimmune, LLC, Hopes T-cell Therapies Will Lead to Approval Difficult to treat solid tumors with adoptive T-cell at Annual Meeting 2018.

Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox is Unique Immunotoxin Fused pseudomonas exotoxin with antibody variable at Annual Meeting 2018.

Jon Eckard, PhD, TYME Inc., talks about Four Drug Combination – effects driven by one drug With other drugs supplementing & tweaking biology at Annual Meeting 2018.

Michelle Dawson, MD, AstraZeneca, talks about 75% Overall Response from Moxetumomab 41% of patients had complete response at Annual Meeting 2018.

Rafael G Amado, MD, Adaptimmune, LLC, explains Between 1-5 Billion Cells Given to Patients Cytokine Release Syndrome resolved with antiIL-6 at Annual Meeting 2018.

Jon Eckard, PhD, TYME Inc., shares Trial Designed to Target Unique Tumor Biology Most cancer therapies come with side-effects at Annual Meeting 2018.

Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox Pivotal in relapse refractory hairy cell leukemia at Annual Meeting 2018.

Rafael G Amado, MD, Adaptimmune, LLC, explains MRCLS Responded to Active Therapy Treatment Harvested T-Cells transduced with antiviral vector at Annual Meeting 2018.

Jon Eckard, PhD, TYME Inc., explains Ongoing Phase II Pancreatic Cancer Trial Metabolic therapy is tumor-treating, patient-sparing at Annual Meeting 2018.

Michelle Dawson, MD, AstraZeneca, talks about Acalabrutinib (Calquence) Approved For relapsed or refractory mantle cell lymphoma at Annual Meeting 2018.

Rafael G Amado, MD, Adaptimmune, LLC, explains Infusion of T-Lymphocytes with T-Cell Receptor MRCLS could be sensitive to therapy at Annual Meeting 2018.

Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., talks about Many Drugs Being Looked at for Multiple Myeloma CD38 and Venetoclax at Annual Meeting 2018

Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, shares Myxoid Round Cell Liposarcoma Expresses NY-ESO-1 T-Cell therapy targeting NY-ESO-1 can induce response at Annual Meeting 2018

Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about Adjuvant Data Changing Clinical Practice Moving into Anti-PD-1 monotherapy, and BRAF at Annual Meeting 2018

Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Trials of BCMA BiTE Platform & CAR-T Cell Early trials hope to provide significant benefit at Annual Meeting 2018

Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, talks about Creating a number of followup studies Testing checkpoint Inhibitors, PD-1 blockade

Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, shares Economics Outcome Research More Important Guiding clinicians & policy makers, survival benefits at Annual Meeting 2018

Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Lots of Patients with Refractory Sarcomas Considering Off-Label Checkpoint Inhibitor

Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about Data is Hypothesis-Generating Data is still useful for determining optimal sequences at Annual Meeting 2018

Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Safety Profile of Once-Weekly Regimen Was comparable opposed to the twice-weekly regimen at Annual Meeting 2018

Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Undifferentiated Pleomorphic Sarcoma Can respond to checkpoint blockade like pembrolizumab at Annual Meeting 2018

Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about ECOG-ACRIN EA6134 Ipilimumab + Nivolumab vs. Dabrafenib + Trametinib at Annual Meeting 2018

Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Novel Endpoints in MRD in Multiple Myeloma Novel Drugs Targeting BiTE Platform at Annual Meeting 2018

Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Sarcoma Subtypes React to Different Immunotherapy Have inflammatory tumor-immune micro-environments at Annual Meeting 2018

Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, shares Economic Outcome Analysis for BRAF Melanoma Anti-CD4+PD-1, & Anti-PD-1 both followed by BRAF-MEK at Annual Meeting 2018

Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., discusses Data from ARROW Trial for Multiple Myeloma Progression-free survival with KYPROLIS at Annual Meeting 2018.

Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.

Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III NSCLC.

Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Gentlemen’s Study Originally for All Men in WA Now available nationwide at Annual Meeting 2018.

Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Areas of Research in 2018-19 include Combination therapy, CARP Inhibitors, radiopharmaceuticals at Annual Meeting 2018.

Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Waldenstrom Macroglobulinemia is Rare Disease Results of study are the most clinically relevant at Annual Meeting 2018

Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Combination Study of Olaparib & Abiraterone Especially for patients with DNA repair alterations at Annual Meeting 2018.

Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, talks about Better Defining Nature of Mutations of Genes Such as MYD88 & CXCR4 at Annual Meeting 2018

Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Acalabrutinib is Another BTK Inhibitor Active drug for Waldenstrom Macroglobulinemia at Annual Meeting 2018

Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Further Characterize Identified Mutations A lot of work to be done beyond the study at Annual Meeting 2018.

Chuck Wiseman, MD, BriaCell Therapeutics, talks about Rollover Protocol Approval Bria-IMT in combination with a checkpoint inhibitor at Annual Meeting 2018.

Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, talks about Devising Future Trials That Add Another Agent Potentially Carfilzomib, Venetoclax, & Bendamustine at Annual Meeting 2018

Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Underserved & Underepresented Patient Population African-Americans have higher risk of prostate cancer at Annual Meeting 2018.

Chuck Wiseman, MD, BriaCell Therapeutics, discusses Capitalizing on Matching HL-Antigens Key to developing clinically relevant immune response at Annual Meeting 2018

Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains BTK Inhibitors Associated with Atrial Fibrillation Only 4% of patients had to go off-study at Annual Meeting 2018

Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, explains how Patients Can Learn More About Gentlemen’s Study from www.gentlemenstudy.org at Annual Meeting 2018.

Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Ibrutinib & Rituximab is a new standard for WM Design trials that use the combination as a backbone at Annual Meeting 2018

Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Gentlemen’s Study for Metastatic Prostate Cancer Trial offers testing in a web-based, phone-based manner at Annual Meeting 2018.

Chuck Wiseman, MD BriaCell Therapeutics, discusses Cell Preparation Bria-IMT Confirms that similar vaccine therapies can regress advances at Annual Meeting 2018

Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Innovate Trial – Randomized Placebo Control 150 patients with Waldenstrom Macroglobulinemia at Annual Meeting 2018

Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC

Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses New Treatments for Prostate Cancer Identified from Tumor & Germline or Inherited sequencing at Annual Meeting 2018.

Application of 2% Sequester Cut to Medicare Part B Drug Reimbursement is Unconstitutional and Illegal; Costing Seniors and Taxpayers Billions The Community Oncology Alliance (COA) has filed a lawsuit in the U.S. District Court for the District of Columbia to stop the United States Department of Health and Human Services (HHS) and the White House Office of Management and Budget (OMB) from applying the Medicare sequester cut to reimbursement for Part B drugs. In the lawsuit, COA, which represents more than 5,000 independent, community-based oncologists, shows the sequester cut has harmed patients, decimated the nation’s independent community cancer care system, and cost…

Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Genome Sequencing Enable a Complete Picture Additional analyses not found on other platforms at AACR 2018

Chinthalapally V. Rao, PhD, Stephenson Cancer Center, talks about Marginal Beneficial Effects After 6 Months to 1 Year Limitations of high-dose are side-effects at AACR 2018

Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Researchers Upload Data With St. Jude Cloud Goal is to Enable Datasharing for Pediatric Cancer at AACR 2018

Scott Newman, PhD, St. Jude Children’s Research Hospital, explains What is St. Jude Cloud? Bring tools to the data & doing analyses in a secure cloud at AACR 2018

Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Access, Analyze, & Visualize Genomic Data Offer 5,000 Genome sequencing datasets worldwide at AACR 2018

Chinthalapally V. Rao, PhD, Stephenson Cancer Center, talks about Aspirin Prevents Colorectal Cancer Progress Patients subconsciously taking aspirin may cause GIB at AACR 2018

Paul A. Northcott, PhD, St. Jude Children’s Research Hospital, explains Examples of Genes Activated by Enhancer Hijacking Validate findings based on genomic data at AACR 2018

Scott Newman, PhD, St. Jude Children’s Research Hospital, explains St. Jude Cloud Reanalyzed coding variants Some B-Cell ALL have mutational signature at AACR 2018

Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Cloud-Computing – Centralized Infrastructure Enables access of data for all research institutes at AACR 2018

Paul A. Northcott, PhD, St. Jude Children’s Research Hospital, explains Linking Aberrations to Oncogene De-Regulation Unable to make 1-to-1 correlation at AACR 2018

Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, talks about MD Anderson Provides Screenings for Therapies Reviewed by Precision Oncology Decision Support team at AACR 2018

Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Next Meeting will Showcase Modern Technology Next generation sequencing & computational approaches at AACR 2018

Paul A. Northcott, PhD, St. Jude Children’s Research Hospital, explains Novel Mechanisms of Oncogene De-Regulation Integrative Genomic Approaches to implicate new genes at AACR 2018

Emily L. Harris, Ph.D., M.P.H.,National Cancer Institute – Deputy Associate Director, explains ARA Process for Large Budget Grants Program director works with you for details on sharing plan at AACR 2018

Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks Cancer Care for Pediatctrics and Young Adults Rare diseases in this subset patient population at AACR 2018

Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.

Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, talks about Understanding Intratumor Heterogeneity Founding ubiquitous mutations vs. heterogeneous events at AACR 2018

Dr. Nasser Hanna, Indiana University Health, discusses the possible role of immunotherapy in locally advanced NSCLC.

Emily L. Harris, Ph.D., M.P.H., National Cancer Institute – Deputy Associate Director, explains Three Main Data Sharing Policies Large Budget Studies, Genomic Research, & Moonshot at AACR 2018

Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, talks about Abnormalities With Next-Gen Sequencing Widen therapeutic options by tailoring trials to aberrations at AACR 2018.

Elaine R. Mardis, PhD, The Institute for Genomic Medicine, explains 80% of Patients Don’t go to Tertiary Centers Making sure every patient has access to information at AACR 2018

Emily L. Harris, Ph.D., M.P.H.,National Cancer Institute – Deputy Associate Director, explains NIH Data Sharing Accelerates Research Progress Sharing broadly with other researchers to analyze data at AACR 2018

Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, explains TRK-Inhibitor, Larotrectinib Can administer to patients with TRK-fusions at AACR 2018.

Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Variety of Developments in Cancer Genomics Translate discoveries in cancer genomics for patients at AACR 2018

Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, FDA Approval of Pembrolizumab The 1st approval of a drug that is tumor agnostic at AACR 2018.

Despite major advancements in the understanding of the genetic drivers of acute myeloid leukemia (AML) and the pathophysiology of the disease, standard treatment options for AML patients have not experienced any major changes in the past few decades. Clinicians are often hesitant to send patients into clinical trials if the condition of the patient is unlikely to improve. Here, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, discusses the potential of newly-approved AML drugs on the market and how these drugs may increase clinical trial participation rates. Clinical trials will provide an in-depth understanding…

Gail Roboz, MD, from the Weill Medical College of Cornell University, New York City, NY, explores exciting next-generation agents for the treatment of acute myeloid leukemia (AML), such as guadecitabine, a next-generation DNA hypomethylating agent that has the potential to be more effective than decitabine. A similar concept has previously been used for the development of the CPX-351, a liposomal formulation of cytarabine and daunorubicin, which received FDA approval for the treatment of high-risk AML. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood counts or examining the morphology of the bone marrow is not sufficient to determine the levels of residual leukemic cells remaining upon completion of therapy. Here, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, discusses the importance of assessing the levels of minimal residual disease (MRD) and what these levels can mean to the patient. Dr Roboz also emphasizes the need to quantify MRD in AML across the world, which will help clinicians and…

The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are many issues surrounding the use of chemotherapy drugs in this population. In this interview, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, highlights the challenges of AML treatment in the elderly, and some of the options that can be offered to patients in which high dose chemotherapy will not prove beneficial, or patients who have a low tolerance to intensive chemotherapy. This video was recorded at the 2018 European School of Hematology (ESH) Clinical…

Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, highlights the importance of minimal residual disease (MRD) assessment in predicting the long-term effects of therapy in acute lymphoblastic leukemia (ALL) patients, and the steps that should be followed if a patient is MRD-positive after the administration of CAR T-cell therapy or other forms of treatment. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Unlike childhood acute lymphoblastic leukemia (ALL), there are currently no approved CAR T-cell products for the treatment of adult ALL; here, Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, explains how clinical trials investigating ALL are often scarce and extremely competitive to enroll patients. Dr Frey also shares her excitement about the future of CAR T-cell therapies and the benefits that will follow. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

CAR T-cell therapy has proven effective in delivering high response rates in relapsed acute lymphoblastic leukemia (ALL) patients, but what can be done to move the field forward? Here, Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, discusses the current strategies that are being put in place to mitigate toxicity, such as the early delivery of tocilizumab and modifying the dose of CAR T-cell therapy delivered to the patient. Although the initial response rates to CAR T-cell therapy are high, this form of therapy should also be targeted towards antigens such as CD22, which would decrease the rates…

Treatment outcomes for acute myeloid leukemia (AML) patients treated with immunotherapy have significantly lagged behind those achieved for acute lymphoblastic leukemia (ALL), and this is due to the fact that eliminating the B-cell lineage for the management of ALL is less problematic than eliminating the myeloid lineages involved in AML. In this interview, Marion Subklewe, MD, from the Ludwig-Maximilians University Hospital of Munich, Munich, Germany, explores the antigens targeted for the treatment of ALL, such as CD22, CD20 and CD19. Dr Subklewe also discusses the other factors that play a role in choosing the right AML targets, including cofactors and…

Despite recent approvals of drugs targeting acute myeloid leukemia (AML), overall survival and complete remission rates remain suboptimal. In this interview, Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains how he encourages his AML patients to participate in clinical trials, especially those who are in a relapsed or refractory state. Patients are more hesitant to participate in randomized, placebo-controlled trials because there is no guarantee that they will receive the active drug, and due to the general commitments associated with trial participation. This video was recorded at the 2018 European School of Hematology (ESH)…

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the mechanisms of resistance to targeted therapies such as enasidenib and ivosidenib in acute myeloid leukemia (AML). Primary resistance, defined by a complete lack of response to the drug, is mediated by co-occurring mutations and is most common in patients with FLT3, JAK and Ras mutations. Secondary resistance, where the patient relapses after achieving remission on the drug, is primarily mediated through the clonal outgrowth of different clones, such as different FLT3, Ras or isocitrate dehydrogenase (IDH) mutations. This video was recorded at the 2018 European…

The side effects of isocitrate dehydrogenase (IDH) inhibitors for the treatment of acute myeloid leukemia (AML) include gastrointestinal toxicity, leukocytosis, differentiation syndrome and QT prolongation, among many others. Here, Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains how these side effects are minimal and well tolerated in most patients. Dr Stein highlights how differentiation syndrome, characterized by symptoms such as unexplained fever, weight gain and peripheral edema, should be addressed immediately with high doses of steroids. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held…

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains the mechanisms of isocitrate dehydrogenase (IDH) mutations and their effect on myeloid differentiation, ultimately leading to the phenotype of acute myeloid leukemia (AML). Targeting the IDH mutation, using IDH inhibitors, may lead to the reversal of this differentiation blockade. Dr Stein discusses the IDH2 inhibitor enasidenib, which received FDA approval last year for the treatment of relapsed and refractory AML, and the IDH1 inhibitor ivosidenib, which is currently under FDA review. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on…

Traditionally, the standard therapy for the management of acute myeloid leukemia (AML) in elderly patients has been low-dose cytarabine, but hypomethylating agents (HMAs) have quickly become the backbone of AML treatment in many countries. Here, Chrisoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, provides evidence for the efficacy of HMAs in the elderly and those with unfavorable cytogenetics, including an increased tolerability and decreased toxicity when compared to intensive chemotherapy. Early clinical trials into HMAs combined with other drugs, such as venetoclax, have demonstrated increased complete remission rates and prolonged survival in elderly AML patients. This…

Minimal residual disease (MRD) is a highly important prognostic indicator used to determine treatment efficacy in acute myeloid leukemia (AML) patients. Here, Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses the benefits and disadvantages of the common techniques used to measure MRD today, including next-generation sequencing and flow cytometry. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood counts or examining the morphology of the bone marrow is not sufficient to determine the levels of residual leukemic cells remaining upon completion of therapy. Here, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, discusses the importance of assessing the levels of minimal residual disease (MRD) and what these levels can mean to the patient. Dr Roboz also emphasizes the need to quantify MRD in AML across the world, which will help clinicians and…

Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different strategy to classical chemotherapeutic agents, and the development of other similar drugs is expected to drastically improve the outcomes of patients with AML. In this interview, Chrisoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, also discusses treatments that have recently received FDA approval, such as CPX-351, a liposomal formulation of cytarabine and daunorubicin that has been approved for the treatment of secondary AML in the US, and isocitrate dehydrogenase (IDH) inhibitors. This video was recorded at…

Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses how his team is carrying out treatment optimization trials to match established acute myeloid leukemia (AML) therapies to the ideal patient population. This initiative involves comparing dosing schedules of available drugs and establishing which patients will benefit from allogeneic stem cell transplantation. Newly FDA-approved drugs are also being examined to see if they can be combined with standard regimens to tackle relapse and resistance. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, explains how the lack of novel drugs for the treatment of acute myeloid leukemia (AML) in the past 50 years has led to increased research into combination therapy using existing drugs. Different dosing schedules of available AML drugs are now being used to improve patient outcomes, but extensive research into new therapiesis needed to further increase response rates. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, discusses ways of improving the outcomes of patients suffering from B- cell acute lymphoblastic leukemia (ALL) and other B-cell disorders using CAR T-cell therapy. Therapy should be offered as early as possible before relapse has occurred and before initial diagnosis to avoid the effects of high-dose chemotherapy. B-cell ALL target antigens including CD19 have also been proven to demonstrate efficacy in ALL patients and should be considered when…

Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker in predicting patient outcomes. MRD can aid in tailoring therapies according to initial treatment response. This risk-adapted approach to therapy has been shown to reduce the poor outcomes associated with high-risk subtypes of ALL. In this interview, Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, highlights the importance of MRD monitoring and the new techniques that are being used to measure MRD in ALL patients, such as sequencing-based approaches. Recorded at the 2018 European…

Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, discusses the novel and interesting approaches for first-line therapy, in acute lymphoblastic leukemia (ALL) patients treatments given to those who have relapsed. The monoclonal antibody, rituximab, has been found to increase survival rates in adult ALL patients, and reduce allergic reactions to the chemotherapeutic agent, asparaginase. As a therapy targeted towards a specific mutation, kinase inhibitors have been found to be effective in ALL subtypes such as BCR-ABL-positive ALL and Philadelphia chromosome-positive ALL. Dr Mullighan also emphasizes the need to use different immunotherapy techniques upon poor…

Finding the right treatment for a specific subset of acute lymphoblastic leukemia (ALL) requires a correct diagnosis, but there are many challenges that clinicians face when trying to implement precision medicine. ALL subsets are not as easily identified in comparison to other leukemias, as the various genetic changes that occur in ALL, such as chromosomal rearrangements, deletions of DNA and sequence changes, are challenging to identify. Charles Mullighan, MBBS (Hons), MSc, MD, explains how the team at St. Jude Childrens Research Hospital, Memphis, TN has taken a different approach to diagnosing new ALL patients. Recorded at the 2018 European School…

Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, provides an overview of his talk presented at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, where he discussed the advancements in the molecular classifications of acute lymphoblastic leukemia (ALL) with an increased understanding of the genetic drivers of the disease. The identification of the complex mutations that accompany the different subtypes of ALL have also allowed for a better prognosis for both childhood and adult ALL, as available therapies can be tailored to the patient.

Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the importance of collaborating with other trial groups that are focusing on acute leukemias by joining efforts with other experts at various networking events and conferences. Recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Midostaurin is a tyrosine kinase inhibitor that has been newly approved for the treatment of acute myeloid leukemia (AML). In this interview, Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the process of organizing the midostaurin clinical trials by collaborating with experts throughout North America, Europe and Australia (NCT00651261). Although midostaurin is already FDA-approved, analysis of the collected data from the trials is still being carried out to find out the causes of a low response to the drug, which may lead to a further understanding of AML in the future. Recorded from the 2018 European School…

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, explains how CAR T-cell therapy might not prove effective in acute myeloid leukemia patients if healthy hematopoietic stem cells are targeted. His research group is now looking into special gene-modified autologous dendritic cells that have increased activity towards WT1, a tumor antigen that is expressed at high levels in various acute and chronic leukemias.

Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the research carried out by some of his former mentees that identified the IDH1 mutation as a novel therapeutic target in acute myeloid leukemia (AML). As Prof. Ganser explains, the genetic changes that occur in AML are now becoming better understood through enthusiastic young researchers and medical students that are willing to explore exciting new topic areas. This interview was recorded at 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Dealing with patients with refractory acute myeloid leukemia (AML) or with those who have relapsed, is challenging, and stem cell transplantation is one of the few therapies that can be offered in these instances. However, most patients who have relapsed are too old to undergo this procedure, so palliative care must be offered in its place to relieve existing symptoms and improve quality of life. Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany explains how the right balance should be achieved when using aggressive forms of therapy, because mechanisms of resistance in AML are not yet fully understood.…

Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany talks about his experience of the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, where he discusses the quality of the presentations being held at the event, the exciting conversations with other experts such as current controversies surrounding acute leukemia research, and the overall atmosphere of the conference.

Dr. Nasser Hanna, Indiana University Health, addresses the issue of prophylactic cranial irradiation (PCI) in locally advanced NSCLC.

Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Big Shoes to Fill as President of AACR Association is over 110 years old at AACR 2018

Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains KLLN & SEC23B Novel Predisposition Genes Prediction tools for cancer and autism at AACR 2018.

Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains SEC23B is Altered For Rare Blood Disorder Type II Congenital dyserythropoietic anemia at AACR 2018.

Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains SEC23B is Very Rarely Studied in Cancer Enters the nucleus and plays other roles at AACR 2018.

Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains KLLN is Right Next to PTEN Gene Might play a role in DNA damage response at AACR 2018.

Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains 3D Modeling of PTEN Tumor Suppressor at AACR 2018.

How Do Thoracic Surgeons Assess Fitness for Surgery

Dr. David Harpole, Duke University Medical Center, describes the mediastinoscopy and its use in lung cancer staging.

Dr. David Harpole, Duke University Medical Center, describes the sleeve resection and how it can help selected patients with large tumors retain lung function.

Dr. David Harpole, Duke University Medical Center, defines the concept of mediastinal node sterilization and its use after neoadjuvant therapy.

Dr. David Harpole, Duke University Medical Center, compares traditional open thoracotomy with video-assisted thorascopic surgery, highlighting the advantages of the newer approach.

Dr. Benjamin Levy, Mount Sinai Health Systems, lists the goals of treating advanced NSCLC and the methods used to achieve those goals.

Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothelioma at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting.

How Rate of Progression Can Affect Treatment Decisions

Dr. Jack West reviews his top 5 abstracts in the advanced NSCLC track at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting.

Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases in lung cancer.

Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.

Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.

Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

Scott Kopetz, M.D., Ph.D., FACP, discusses Safety Lead-In from the Beacon Study 48% Overall Response Rate

Scott Kopetz, M.D., Ph.D., FACP, explains Less Predictable Alternate BRAF Mutations Not all BRAF mutations are the same.

Scott Kopetz, M.D., Ph.D., FACP, discusses Getting Patients into Clinical Trial Sooner than Later Start with aggressive cytotoxic backbone

Scott Kopetz, M.D., Ph.D., FACP, explains the Rare Clones of KRAS Mutant Cells Able to identify resistant clones

Scott Kopetz, M.D., Ph.D., FACP, explains BRAF V600E Mutation BRAF with EGFR Provided Synergy.

Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.

Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

Community Oncology Alliance Statement on President’s Blueprint to Lower Drug Prices Putting Cancer Patients First and Lowering Drug is Critically Important, Community Oncology Supports Blueprint and is Working on Solutions Administration Must Fix and Avoid Past Policy Mistakes That Have Contributed to Ongoing Problems with Cancer Care System Washington, DC – Friday, May 11, 2018 – The Community Oncology Alliance (COA) released the following statement regarding President Donald Trump’s recently announced blueprint to lower drug prices and reduce out-of-pocket costs. COA strongly supports President Trump and the Administration’s work to put patients first and lower the price of prescription drugs.…

Community Oncology Alliance Names Dr. Frederick M. Schnell to Newly Created Medical Director Position Experienced Community Oncologist Will Provide Valuable Guidance on Patient Care and Practice Operations Washington, D.C. – February 22, 2018 – The Community Oncology Alliance (COA) announced today that Frederick M. Schnell, M.D., F.A.C.P., has been appointed to the newly created staff position of Medical Director. He brings more than three decades of experience as a physician and community oncology practice CEO. Among the first issues Dr. Schnell will help community oncology practices address is the future of oncology payment reform. Previously, Dr. Schnell was a practicing…

Community Oncology Alliance Statement on White House Budget Proposal Drug Price Recommendations Administration’s Budget has Numerous Smart, Overdue Policy Solutions; but Certain Medicare Part B Proposals Ignore History and will Backfire  Washington, DC – February 13, 2018 – Today, the Community Oncology Alliance (COA) released the following statement regarding the White House’s proposed budget recommendations and a recent report from President Trump’s Council of Economic Advisors on strategies to reform biopharmaceutical pricing. Ensuring patients can afford and access life-saving therapies to fight cancer is a top concern for oncologists, nurses, practice administrators, and other cancer care professionals. Every day we…

Journalist, author and television host Joan Lunden sat down with COA executive director Ted Okon to discuss her latest book “Had I Known: A Memoir of Survival.” Here she discusses key things readers should take away from the book.

Scott Hamilton discusses the importance of the health care industry and everyone on the cancer care team.

COA Cancer Policy Minute with Ted Okon This Cancer Policy Minute video is part of Community Oncology TV.

Pharmacy Benefit Managers (PBMs): Abusive Middlemen COA Cancer Policy Minute with Ted Okon

Did you know that the majority of Americans battling cancer receive their care in what is known as a community oncology practice?

COA Patient Advocacy Network (CPAN) advocates talk about what being a part of CPAN means to them.

COA Cancer Policy Minute with Ted Okon. This Cancer Policy Minute is part of the Community Oncology TV series.

Community oncology practice New England Cancer Specialists (NECS) is always looking forward, providing high quality, data-driven, low cost cancer care.

Community oncology practices like Augusta Oncology take care of the whole patient, from diagnosis and treatment to social and financial issues.

NFL linebacker and Super Bowl champion Mark Herzlich of the New York Giants sat down with with COA executive director Ted Okon. Here he talks about his cancer journey and advice for others fighting cancer.

NFL linebacker and Super Bowl champion Mark Herzlich of the New York Giants discusses how he created a team of caregivers, doctors, nurses, family, and friends who were there for him when battling cancer.

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.

Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology

Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads this section on new data concerning Lurbinectedin of a three part series dedicated to the advancements in treatment of small cell lung cancer. The discussants include Anne Chiang MD, PhD, Associate Professor, Yale University School of Medicine, Deputy Chief Medical Officer, Chief Network Officer, Smilow Cancer Hospital, Taofeek Owonikoko, MD, PhD, MSCR, Professor, Department of Hematology & Medical Oncology, Emory University School of Medicine, Co-Chair, Clinical & Translational Review Committee, Winship Cancer Institute of Emory University, Jeff…

H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads this section on immunotherapy of a three part series dedicated to the advancements in treatment of small cell lung cancer. The discussants include Anne Chiang MD, PhD, Associate Professor, Yale University School of Medicine, Deputy Chief Medical Officer, Chief Network Officer, Smilow Cancer Hospital, Taofeek Owonikoko, MD, PhD, MSCR, Professor, Department of Hematology & Medical Oncology, Emory University School of Medicine, Co-Chair, Clinical & Translational Review Committee, Winship Cancer Institute of Emory University, Jeff Petty, MD, Director,…

H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads this section on ROVA-T of a three part series dedicated to the advancements in treatment of small cell lung cancer. The discussants include Anne Chiang MD, PhD, Associate Professor, Yale University School of Medicine, Deputy Chief Medical Officer, Chief Network Officer, Smilow Cancer Hospital, Taofeek Owonikoko, MD, PhD, MSCR, Professor, Department of Hematology & Medical Oncology, Emory University School of Medicine, Co-Chair, Clinical & Translational Review Committee, Winship Cancer Institute of Emory University, Jeff Petty, MD, Director,…

H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads a roundtable discussing newly released data on Lurbinectedin, ROVA-T, and emerging immunotherapies within small cell lung cancer treatments. This clip is the entire virtual roundtable with all topics discussed in detail. The panel includes Anne Chiang MD, PhD, Associate Professor, Yale University School of Medicine, Deputy Chief Medical Officer, Chief Network Officer, Smilow Cancer Hospital Taofeek Owonikoko, MD, PhD, MSCR, Professor, Department of Hematology & Medical Oncology, Emory University School of Medicine, Co-Chair, Clinical & Translational Review…

Thrombotic microangiopathy (TMA) is a rare complication that may arise post-transplant in patients, however, incidence of TMA has increased in recent years with no clear reason. Speaking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Enric Carreras, MD, PhD, from the Hospital Clinic of Barcelona, Barcelona, Spain, analyses the current knowledge of TMA complications and discusses the potential of various therapeutic options available, including tacrolimus, rituximab and eculizumab.

The complications in blood and marrow transplantation can be serious with rapid onset, therefore ideal donor matching is crucial in minimizing complications. In this talk, Enric Carreras, MD, PhD, from the Hospital Clinic of Barcelona, Barcelona, Spain, outlines the process of donor selection for blood and marrow transplants and the variables to be considered in selecting ideal donors. This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, discusses the key reasons why EBMT 2018 has been a success. Mohamad talks about the attention that the latest treatment options including CAR-T therapy are receiving and how, together with managing complications, patient outcomes can be improved.

There has been an increase in the number of patients with refractory hematological malignancies being referred to transplant centers, although previously, treatment was limited for refractory conditions. In this talk, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, alludes to the optimism regarding allogeneic therapy for patients with refractory hematological malignancies. Talking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Prof. Mohty discusses the potential candidates for allogeneic transplantation.

The therapeutic landscape of Hodgkin lymphoma has improved considerably over the past 50 years, with patient outcomes improving due to accurate diagnoses. Here, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, raises the issue that not all patients respond in the same way to therapy. Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Prof. Mohty discusses the factors that may introduce complications in therapy response, and how novel therapies may hold the key in delivering tailored care to patients.

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging

Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.

Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.

Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer

1st Video in the GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD. Dr. West moderates this roundtable discussion highlighting studies presented at ASCO 2016.

2nd video in GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD. Dr. West moderates the subject of if online groups help speed development of new targeted therapies.

Disease relapse is a significant cause of transplant failure in patients with acute myeloid leukemia (AML). Talking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, stresses the importance of managing relapse and how it may be achieved. Prof. Craddock mentions the exciting opportunities present to improve patient outcomes, but only with the use of clinical trials.

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, outlines the breakthrough therapies for the treatment of acute myeloid leukemia (AML) in adults, including midoastaurin in patients with a FLT-3 mutation, vyxeos for patients with secondary AML, and IDH2 inhibitors. This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

Cure Leukemia is a leading center for the development of new drug and transplant treatments for patients with hematological cancers. Its aim is to improve the access to the latest clinical trials for patients in the UK with the assistance of research nurses, who play a pivotal role in recruiting patients for transplant clinical trials. In this talk, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, mentions the recognition Cure Leukemia has received and why its role is crucial. Prof. Craddock was speaking from the 2018 European Society for Blood and Marrow…

There is a desperate need for rapid turnaround of transplant clinical trials to bring forward breakthrough therapies. IMPACT is a new partnership that aims to improve regulation and transplant outcomes. Speaking here, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, introduces key trials that will be starting soon, including the PRO-DLI trial (NCT02856464), a trial investigating CPX-351 for untreated acute myeloid leukemia (NCT03335267). This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

4th video in GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD. Dr. West moderates the discussion featuring local consolidation therapies for Oligometastases.

Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses the reasons behind using adjuvant chemotherapy for early stage NSCLC patients. Clinical studies have shown that adding chemotherapy after surgery for lung cancer can indeed improve survival.

Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).

Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses using adjuvant chemotherapy for elderly and frail patients. What was seen in particular in the trial performed by NCI Canada, using cisplatin with navelbine chemotherapy, was that people who were considered elderly were able to achieve just as much benefit from chemotherapy in terms of survival as younger people did.

Ruben Niesvizky, MD, explains Incorporating Different Schedules into Combinations Use minimum active dose at Imedex Great Debates 2018.

Ruben Niesvizky, MD, explains Quadruple Agents in Relapse Refractory Myeloma Capitalizing on synergy & lack of toxicities at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains One Size Does Not Fit All in Myeloma Clonal Tiding & Complex Heterogeneity at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Early Transplant Confers PFS Benefit, but Not Overall Stem cell transplant is an option at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Combinations with RVD Beyond Daratumumab Data with ixazomib, revlimid, & dexamethasone at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids at Imedex Great Debates 2018.

Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).

Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses the topic of lung cancer and that there is an entire spectrum of different kinds of cancers that have started inside the lungs. Small cell lung cancers behave very differently than non-small cell lung cancer.

On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our first video welcomes all to the event, and it was our extreme pleasure to have Chris Draft and Dr. Ross Camidge join us to start the day! This is followed by Does NED matter? Using curative surgery or radiation techniques to treat “incurable” advanced lung cancer, with Dr. Rob Meguid, and a panel discussion featuring Dr. Meguid, Dr. Chad Rusthoven,…

Paul G. Richardson, MD, explains Selinexor is a Novel Mechanism of Action Venetoclax Serves a Challenging Population at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Powerful new IMiDs, CC-220 & CC-92480 Importance of Small Molecules in advanced trials at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Melflufen is a Modified Derivative of Melphalan Peptidase-avid and a targeted form of chemotherapy at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Selinexor is an Inhibitor of Nuclear Export Proteins Synergy with Bortezeomib on anti-myeloma activity at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Venetoclax Shown Great Results with Bortezomib It targets 11;14, oral, well-tolerated at Imedex Great Debates 2018.

On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our second video is the first part of the forum breakout session for ALK + patients and caregivers, featuring Dr. Shirish Gadgeel and patient moderator Linnea Olson.

GRACE is happy to present the 9th and final video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Jose F. Leis, MD, PhD, explains how Control of disease can be achieved with Ibrutnib High-risk Relapsed Refractory patients will progress at Imedex Great Debates 2018.

Richard R. Furman, MD, talks about how MBL Patients Don’t Need Bone Marrow Biopsies MBL can be followed by CBCs and Physical Exams at Imedex Great Debates 2018.

Amer M Zeidan, MBBS, explains 4 New Drugs in the Treatment Landscape for AML Incorporating the new drugs in to AML management at Imedex Great Debates 2018.

Jose F. Leis, MD, PhD, explains Venetoclax Rapidly Moving as Best 2nd-line Therapy SCT still remains as the only curative treatment Imedex Great Debates 2018.

Matthew S. Davids, MD, MMSc, talks about how Venetoclax w Rituximab progressed the furthest Phase 3 Data shows the combination is superior Imedex Great Debates 2018.

Richard R. Furman, MD, talks about how MBL Patients Don’t Need Bone Marrow Biopsies MBL can be followed by CBCs and Physical Exams at Imedex Great Debates 2018.

Jose F. Leis, MD, PhD, explains PET-Scans Not as Specific for Richter’s Transformation Biopsies are essential for those who fail new therapies at Imedex Great Debates 2018.

Amer M Zeidan, MBBS, talks about A lot of Questions on the Best Use of New Drugs Still waiting on more data, stick to the label at Imedex Great Debates 2018.

Matthew S. Davids, MD, MMSc, explains Role of Chimeric Antigen Receptor T Cells CAR-T Cell after multiple novel agent-based therapies at Imedex Great Debates 2018.

Richard R. Furman, MD, explains how Prognostics are difficult in the MBL population Del17P & NOTCH1 are relevant for time to treatment at Imedex Great Debates 2018.

Amer M Zeidan, MBBS, explains Enasidenib, an IDH2 Inhibitor based on Phase 1 Trial High-Response rate in patients with IDH2 mutation at Imedex Great Debates 2018

Jose F. Leis, MD, PhD, explains the Treatment of CLL & Richter’s Transformations High Risk Patients will progress their disease at Imedex Great Debates 2018.

Richard M. Stone, MD, talks about Incorporating Midostaurin for FLT3 Positive Patients Use Gemtuzumab Ozogamicin for CD33 Expression at Imedex Great Debates 2018.

GRACE is happy to present the 7th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

GRACE is happy to present the 6th video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss whether current evidence supports favoring proton beam radiation.

http://cancerGRACE.org/

GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.

3rd video in GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD. Dr. West moderates the subject of urine or blood test vs lung biopsy, and finding EGFR mutations.

In this sixth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the breakout session for EGFR patients and caregivers, featuring Drs.Greg Riely Jack West, and patient moderator Bob Fuerst.

In this eighth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the lunchtime keynote discussion: The Evolving Landscape of Molecular Testing in Lung Cancer: Who, How and When? featuring Dr. Dara Eisner.

In this seventh video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the lunchtime Lung Cancer Champion Award presented to Chris Draft by GRACE founder, H. Jack West.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joined GRACE to discuss the basics of lung cancer for Spanish speaking patients and caregivers. In this video, Dr. Santana-Davila joined GRACE to discuss the general approach to limited stage small cell lung cancer.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joined GRACE to share information on the general approach to extensive stage small cell lung cancer for Spanish speaking patients and caregivers.

In this ninth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The first video from these sessions is Bankruptcy and Workplace Discrimination, presented by Patricia McMahon and Carlos Colon, AFC.

In this tenth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The second video from these sessions is The Cancer Kitchen, with Lisa Wingrove, RD, CSO. Lisa is joined in this video by her lovely kitchen helper, Chris Draft.

In this twelfth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The fourth video from these sessions is Dealing with Down Days, presented by Jeanice Hansen, MSW, LCSW, OSW-C.

During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. In this fifth video we feature our friend Rita Johnson

During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. In this first video we feature our friend Linnea Olson.

During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. In this third video we feature our friend Don Fredal

During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. In this sixth video we feature our friend Ann Broo.

In this thirteenth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The fifth video from these sessions is Exercise for Lung Cancer Patients, presented by Jeffrey Eagan DPT.

In this eleventh video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The third video from these sessions is Chemo Brain, with Denise Damek, MD.

In this fourteenth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The sixth video from these sessions is Love, Sex and Cancer, presented by Dr. Helen Coons.

In this sixteenth and final video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The eighth video from these sessions is Recharging the Caregivers Batteries, with Jeanice Hansen, MSW, LCSW, OSW-C.

Dramatic progress has been made in our understanding of the clinical, biological and molecular heterogeneity of chronic lymphocytic leukemia (CLL). Despite this, treatment challenges remain, particularly in patients with high-risk disease. This Velocity Vlog activity featuring Dr. John N. Allan addresses the question of how to integrate the latest knowledge into clinical practice to help guide treatment choices for patients with high-risk CLL. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=CLL © 2018 Imedex, LLC.

On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung Cancer Initiative of North Carolina, to discuss with top providers the newest information on Squamous Cell Lung Cancer. This webcast was made available live online, and we are excited to present the videos, now available for viewing. Our first presentation discusses what is squamous lung cancer, with Chad Pecot, MD.

On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung Cancer Initiative of North Carolina, to discuss with top providers the newest information on Squamous Cell Lung Cancer. This webcast was made available live online, and we are excited to present the videos, now available for viewing. Our second presentation discusses currently available treatment options, with Jared Weiss, MD.

On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung Cancer Initiative of North Carolina, to discuss with top providers the newest information on Squamous Cell Lung Cancer. This webcast was made available live online, and we are excited to present the videos, now available for viewing. Our third presentation discusses future directions in treatment, with Chad Pecot, MD.

Hyperhydration is typically used along with high-dose melphalan in patients undergoing stem cell transplantation. However, the evidence behind this practice is limited and the dosage administered to patients needs refining. In this interview, Midori Nakagaki, BPharm, MSc, from the Royal Brisbane Hospital, Brisbane, Australia, discusses the findings of her groups study retrospectively comparing patients response with hyperhydration vs. without hyperhydration. Midori emphasizes the advantages in reducing dosage, namely easing the workload for healthcare professionals and minimizing the pressures on patients. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal.

The European Society for Blood and Marrow Transplantation (EBMT) have recently set up their dedicated EBMT Patient Advisory and Advocacy Committee, to encourage and support patient and advocate involvement in stem cell transplantation. Here, Anita Waldmann from the Leukaemia Patient-Support Group RHEIN-MAIN, Rüsselsheim am Main, Germany, talks about the Committees recent success and future aims. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal.

Blood and bone marrow transplantation continues to experience breakthroughs, with the role of the patient becoming increasingly important. In this talk, Anita Waldmann from the Leukaemia Patient-Support Group RHEIN-MAIN, Rüsselsheim am Main, Germany, discusses the needs of blood and marrow transplant patients, and why transplant centers should focus on these needs. Speaking from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal, Anita stresses the power of the patients voice in influencing policy.

The Worldwide Network for Blood & Marrow Transplantation (WBMT) is an umbrella organization for institutions and centers carrying out blood and marrow transplants. Here, Anita Waldmann from the Leukaemia Patient-Support Group RHEIN-MAIN, Rüsselsheim am Main, Germany, discusses the role of the WBMT in supporting countries to set up blood and marrow transplant institutions. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal.

Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia, and can present de novo or following the early symptoms of plasma cell myeloma. Patients with PCL tend to present with aggressive clinical features, such as extramedullary disease. Here, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmark, discusses the challenges in treating patients with these aggressive subtypes of multiple myeloma, as optimal therapies havent been designed for this patient population. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.

The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmark, discusses the variety of agents used in the therapeutic management of MM. This interview was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.

Systemic amyloid light-chain (AL) amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly, but treatment and outcomes have not been systematically studied in this group of patients. Here, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the clinical profile and treatment outcomes of this patient population, from an analysis conducted by his group. Dr Merlini highlights the most effective treatment approach indicated by this data. This video was recorded at the 2018 European Myeloma Network (EMN) Meeting, in Turin, Italy.

New insights into the biology of multiple myeloma (MM) are continually emerging. In this interview, Martin Kaiser, MD, of the Institute of Cancer Research, London, UK, covers what is known about Monoclonal Gammopathy of Undetermined Significance (MGUS) and clonal succession in MM. Dr Kaiser then considers whether this could be targeted, particularly in terms of predicting disease progression. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

A large contributing factor to outcome in amyloidosis is the stage of diagnosis. Here, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the need to improve outcomes in patients with very advanced (stage IIIb) cardiac amyloid light-chain (AL) amyloidosis. Dr Merlini emphasises the importance of early diagnosis for this patient population using biomarkers and imaging, to supress the light-chains amyloid deposits early on, and change the outlook of these patients. This video was recorded at the 1st European Myeloma Network Meeting, in Turin, Italy.

This is an exciting time for the treatment of amyloid light-chain (AL) amyloidosis, with a number of novel therapies on the horizon. In this interview, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the novel agents currently in clinical trials, which can target the amyloid deposits characterizing the disease. Dr Merlini highlights NEOD001 (Phase III VITAL study; NCT02312206) and the combination of CPHPC and anti-serum amyloid P component antibodies (NCT01777243). This video was recorded at the 1st European Myeloma Network Meeting (EMN), in Turin, Italy.

New insights into amyloid light-chain (AL) amyloidosis have emerged in recent years. Here, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, gives an overview of the mechanisms behind this rare condition at the 1st European Myeloma Network Meeting (EMN), in Turin, Italy. Dr Merlini then discusses the importance of biomarkers in the reflection of pathogenic mechanisms of AL amyloidosis, highlighting key biomarkers, such as NT-proBNP and GDF-15.

There are now many options to treated relapsed/refractory multiple myeloma (MM); however, these drugs can be costly, and access differs between countries and locations. In this interview, Jean-Luc Harousseau, MD, of the University of Nantes, Nantes, France, discusses the recommendations for and challenges of treating at relapse from a cost/efficacy point of view. Dr Harousseau discusses how this can assessed and understood, as well as how treatment duration is considered and how clinical trials can be designed to optimize this measure. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

As our knowledge of the genetics of multiple myeloma (MM) advances, we can more precisely understand and target the disease. Here, Martin Kaiser, MD, of the Institute of Cancer Research, London, UK, discusses how different classes of genetic abnormalities in MM could be targeted. Dr Kaiser highlights exciting work on the t(4;14) translocation in MM and tissue agnostic therapies.This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

There are an array of new strategies evolving to manage relapsed chronic lymphocytic leukemia (CLL). In this interview, George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the exciting UK CLL Forum analysis of patients treated with ibrutinib at first relapse. Dr Follows highlights the fascinating results identified between patients with early and late relapse. This interview was recorded at the British society for Hematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK.

The treatment of relapsed/refractory lymphoma can prove to be challenging. PEP-C (prednisone, etoposide, procarbazine, and cyclophosphamide) is an oral combination therapy regimen used for such patients. Here, George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the Cambridge University Hospitals and Anglia regional experience of the benefits of using PEP-C over the past 8 years. This interview was recorded at the British society for Hematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK.

An exciting array of data for myeloproliferative neoplasms (MPNs) was presented at the 2018 British Society for Hematology (BSH) Annual Scientific Meeting, held in Liverpool, UK. Speaking from the meeting, Claire Harrison, MD, FRCP, FRCPath, from Guys and St Thomas Hospital NHS Foundation Trust, London, UK, talks about the exciting clinical trials currently being conducted in MPNs. Prof. Harrison discusses a study aiming to improve the management of very young MPN patients, which may be used as a pilot to set up a collaboration across Europe, to rapidly generate data that can be used in further understanding this patient population…